ClinicalTrials.gov
ClinicalTrials.gov Menu

Abnormalities of B Lymphocytes During Systemic Lupus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00401141
Recruitment Status : Completed
First Posted : November 17, 2006
Last Update Posted : August 8, 2008
Sponsor:
Information provided by:
University Hospital, Strasbourg, France

Brief Summary:
Previous experimental data strongly suggest that B lymphocytes have intrinsic abnormalities during lupus in mice spontaneously affected by the disease. This study tries to define these abnormalities by looking at the gene expression profile of purified B lymphocytes from patients with non active systemic lupus , compared with the gene expression profile of purified B lymphocytes from healthy donnors.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Procedure: Blood samples Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Phenotypic Characteristics and Transcriptomas of B Lymphocytes During Non Active Systemic Lupus Erythematosus
Study Start Date : April 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • non active systemic lupus

Exclusion criteria:

  • immunosuppressive drugs
  • more than 10 mg of prednisone per day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401141


Locations
France
Service d'Immunologie Clinique et VIH - Hôpital Civil
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Jean-Louis Pasquali, MD Hôpitaux Universitaires de Strasbourg

ClinicalTrials.gov Identifier: NCT00401141     History of Changes
Other Study ID Numbers: 3156
First Posted: November 17, 2006    Key Record Dates
Last Update Posted: August 8, 2008
Last Verified: August 2008

Keywords provided by University Hospital, Strasbourg, France:
Systemic lupus
B lymphocytes
transcriptomas

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases